Zacks Research Upgrades Zealand Pharma A/S (OTCMKTS:ZLDPF) to “Strong-Buy”

by · The Markets Daily

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday, Zacks reports.

ZLDPF has been the topic of a number of other reports. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

View Our Latest Report on Zealand Pharma A/S

Zealand Pharma A/S Stock Performance

Shares of OTCMKTS ZLDPF opened at $34.87 on Monday. The company has a current ratio of 13.98, a quick ratio of 13.98 and a debt-to-equity ratio of 0.02. The stock has a 50 day simple moving average of $45.33 and a 200-day simple moving average of $46.13. The company has a market cap of $2.49 billion, a PE ratio of 5.78 and a beta of 0.95. Zealand Pharma A/S has a 12-month low of $34.87 and a 12-month high of $83.12.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.

See Also